Clinical trials
Lung Cancer (Suspected or Confirmed) clinical trials
Below are recruiting lung cancer (suspected or confirmed) clinical trials, each written for real people, not researchers. We’re tracking 6,580 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05350748Recruiting
MDS study using detailed tests on blood and bone marrow
This study carefully evaluates people with myelodysplastic syndromes (MDS) and closely related blood disorders using detailed medical, blood, and bone marrow testing. The goal is to better understand these conditions and how they progress, which may help guide future care.
Bethesda, MarylandAges 1 day–120 years - NCT07646821RecruitingPhase 1/Phase 2
Study of two drugs for leukemia with TP53 mutation
This trial tests combining two drugs, ropeginterferon alfa-2b and azacitidine, for people with myelodysplastic syndrome or acute myeloid leukemia that has a TP53 gene change. The treatment may help control the cancer, and the study includes people who are newly diagnosed or whose disease has not responded to prior therapy.
Houston, TexasAges 18 years+ - NCT07437963RecruitingPhase 1/Phase 2
Iberdomide plus chemoimmunotherapy for neuroblastoma that returned or did not respond
This trial tests adding a new drug called iberdomide to an existing chemoimmunotherapy regimen for children and young adults with neuroblastoma that has come back or not responded to treatment. The goal is to see if the combination is safe and more effective than current treatments.
Oakland, CaliforniaAges 1–30 - NCT07878065RecruitingPhase 3
Art and movement to ease anxiety in children with leukemia
This study tests whether art and movement activities can help reduce anxiety in children aged 8-13 who are being treated for acute lymphoblastic leukemia (a type of blood cancer) and are in the third stage of their treatment plan. If your child feels anxious, this program may help them feel calmer and more supported during treatment.
Cairo, Cairo GovernorateAges 8–13 - NCT07326592RecruitingPhase 4
Weekly treatment for emphysema caused by alpha-1 antitrypsin deficiency
This study tests a weekly injection of a protein replacement therapy for adults with emphysema due to alpha-1 antitrypsin deficiency. The goal is to see if this treatment can slow down the loss of lung density over three years.
AalborgAges 18–65 - NCT07619079Recruiting
Registry for people with early colorectal cancer in a polyp
This study collects information from people who have had a malignant polyp removed from the colon. It helps doctors learn more about this early stage of colorectal cancer and may help guide future care.
Basking Ridge, New JerseyAges 18 years+ - NCT07870265Recruiting
Blood test for detecting BRAF mutation in melanoma
This trial tests a new blood test to detect a specific gene change (BRAF V600E) in melanoma that has come back. The test uses a technology called CRISPR to find the mutation in a simple blood draw, which could help guide treatment without needing a tissue biopsy.
Brno, BrnoAges 18 years+ - NCT05773274RecruitingPhase 2
Retreating with 177Lu-DOTATATE radiation versus usual treatment
This trial tests whether repeating a targeted radioactive treatment (177Lu-DOTATATE) works better than standard options in people with metastatic gastroenteropancreatic neuroendocrine tumors. It may help by controlling tumor growth after the first round of this therapy stops working.
Birmingham, AlabamaAges 18 years+ - NCT07686445RecruitingPhase 1
Study of AN4035 for advanced cancers with RAS mutations
This trial tests a new drug, AN4035, for people with advanced cancers that have a RAS mutation and high levels of a protein called CEACAM5. The drug may help shrink tumors or slow their growth.
PerthAges 18 years+ - NCT07714980Recruiting
Acupoint stimulation timing for stomach cancer surgery recovery
This trial tests whether giving a gentle, needle-free acupoint stimulation before or after stomach cancer surgery helps speed up recovery. The stimulation uses a small device on the skin, similar to a tens unit, to support recovery after laparoscopic gastrectomy.
Dongying, ShandongAges 18–80 - NCT06780111RecruitingPhase 1/Phase 2
Combination therapy study for advanced esophageal cancer
This trial tests new drug combinations for people with advanced squamous cell cancer of the esophagus that hasn't been treated yet. It aims to see if these combinations can shrink tumors and help patients live longer.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT05633615RecruitingPhase 2
Testing new drug options after CAR T for aggressive lymphoma
This Phase 2 study tests whether adding or switching drug treatments after CAR T-cell therapy can improve outcomes for people with certain aggressive lymphomas that have come back or did not respond. It mainly looks at who remains disease-stable/partly improved after CAR T and what treatment approach works best next.
Tucson, ArizonaAges 18 years+ - NCT07226986RecruitingPhase 1/Phase 2
Study of AMO959 with Lutetium-177 and ARPI for prostate cancer
This trial tests a new combination therapy for men with advanced prostate cancer that has spread and is no longer responding to hormone therapy. It combines an experimental drug (AMO959) with a targeted radiation treatment (Lutetium-177) and a standard hormone therapy to see if it helps control the cancer.
Los Angeles, CaliforniaAges 18 years+ - NCT07711002RecruitingPhase 3
Saruparib with standard therapy for metastatic hormone-sensitive prostate cancer
This trial tests a new drug called saruparib, which may help keep prostate cancer from growing. It is for men whose cancer has spread and who have already received certain treatments. The study combines saruparib with a standard hormone therapy to see if it works better than the hormone therapy alone.
Hot Springs, ArkansasAges 18 years+ - NCT07186842RecruitingPhase 1/Phase 2
Testing the safety of BNT329 for advanced CA19-9 positive tumors
This trial tests if the investigational drug BNT329 is safe and could help people with advanced solid tumors that make a marker called CA19-9. It is for those who have tried standard treatments and need new options.
Denver, ColoradoAges 18 years+ - NCT07672860RecruitingPhase 2
UDCA to protect kidneys during partial nephrectomy
This clinical trial is testing whether a medicine called ursodeoxycholic acid (UDCA) can help protect the kidneys during partial nephrectomy (removing only the tumor while keeping the healthy part of the kidney). It is for people with early-stage kidney tumors who will have temporary interruption of blood flow to the kidney during surgery.
Nanjing, JiangsuAges 18–75 - NCT07864701RecruitingPhase 1/Phase 2
Study of an experimental drug for MYC-positive advanced cancers
This trial tests an experimental drug (JMBI-001) for people with advanced cancers that have a specific marker called MYC. It aims to see if the drug is safe and effective, possibly shrinking tumors or slowing their growth.
Beijing, Beijing MunicipalityAges 18–75 - NCT07684599RecruitingPhase 3
Maintenance treatment for advanced endometrial cancer
This study tests a new maintenance therapy (mocertatug rezetecan) to help keep endometrial cancer from coming back after initial chemotherapy and immunotherapy. It may help people whose cancer had a good response to first-line treatment.
FukuokaAges 18 years+ - NCT06855277RecruitingPhase 3
AAA817 with hormone therapy for advanced prostate cancer
This trial tests a new combination treatment (AAA817 plus a hormone therapy) against standard care for men with advanced PSMA-positive prostate cancer that has spread and stopped responding to a previous hormone therapy. It may be an option if you haven't had certain prior treatments.
Homewood, AlabamaAges 18–100 - NCT07532525RecruitingPhase 1
Pomalidomide after CAR T for B-cell cancer
This trial tests whether the drug pomalidomide, given as a pill, can help people with B-cell leukemia or lymphoma who have recently received CAR T-cell therapy. The goal is to see if pomalidomide can keep the cancer from coming back, and it may be an option for those whose cancer is not growing but still needs management.
Ann Arbor, MichiganAges 18 years+ - NCT07424833RecruitingPhase 1
Study of APG-3288 for Relapsed/Refractory Blood Cancers
This trial is testing a new drug called APG-3288 for people with certain relapsed or treatment-resistant blood cancers (like CLL/SLL, DLBCL, MCL, WM, MZL, or FL). You may qualify if you've tried at least 2 prior treatments and are looking for a new option.
Los Angeles, CaliforniaAges 18 years+ - NCT07286266RecruitingPhase 3
Testing a new drug for platinum-resistant ovarian cancer
This phase 3 trial tests a new drug, mocertatug rezetecan, against standard treatments for ovarian cancer that no longer responds to platinum chemo. It's for people who have had 1 to 4 prior therapies and may offer a new option if you haven't tried all standard treatments yet.
Randwick, New South WalesAges 18 years+ - NCT02865330Recruiting
Registry study for men on active surveillance for low-risk prostate cancer
This is a registry study that follows men with low-risk prostate cancer who choose active surveillance instead of immediate treatment. It helps doctors understand how safe and effective active surveillance is, including confirming results with repeat biopsies.
ValenciaAges 18–80 - NCT03238378Recruiting
Radiation boost plus warming for recurrent head and neck tumors
This trial tests a “salvage” treatment that combines targeted radiation (brachytherapy) with controlled body warming (hyperthermia) for head and neck cancer that has come back. It may help by better shrinking tumors while fitting the treatment to the tumor’s exact location.
ErlangenAges 18 years+
Hear when a new Lung Cancer (Suspected or Confirmed) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lung cancer (suspected or confirmed)?
- Yes. Clin2 currently lists 6,580 recruiting lung cancer (suspected or confirmed) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lung cancer (suspected or confirmed) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lung cancer (suspected or confirmed) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.